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Previous studies in humans with type 1 diabetes mellitus (T1D) and in nonobese diabetic mice have investi-
gated the beneficial immunomodulatory potential of aerobic physical activity. Performing high volume of aero-
bic exercise may favorably regulate autoimmunity in diabetes. We tested whether increased physical activity 
is a self-sufficient positive factor in T1D subjects. During a 3-month observational period, active (six males; 
40.5 ± 6.1 years; BMI: 24.5 ± 2.1) and sedentary (four males, three females; 35.9 ± 8.9 years; BMI: 25.7 ± 3.8) 
T1D individuals on insulin pump therapy were studied for metabolic, inflammatory, and autoimmune param-
eters. At baseline and at the end of a 3-month period, glycosylated hemoglobin (HbA1c), autoantibodies (anti-
GAD, anti-ZnT8, anti-IA2, and ICA) and proinflammatory cytokines (IL-6 and TNF-a) were evaluated. During 
the third month of the period, physically active T1D patients showed a significant reduction in the average 
glucose levels (−9%, p = 0.025, by CGM) compared to the first month values, and even their hyperglycemic 
episodes (>180 mg/dl) diminished significantly (−24.2%, p = 0.032 vs. first month). Moreover, active T1D sub-
jects exhibited an improved body composition with respect to sedentary controls. No significant changes were 
detected as to the autoimmune and inflammatory profiles. This study confirms the beneficial role of physical 
exercise associated with insulin pump therapy in order to improve metabolic control in individuals with T1D. 
These preliminary positive observations need to be challenged in a prolonged interventional follow-up.
Key words: Physical activity; Type 1 diabetes (T1D); Continuous glucose monitoring (CGM); 
Insulin pump therapy
INTRODUCTION
Type 1 diabetes mellitus (T1D) is a disease character-
ized by an immune-mediated process that contributes to 
the depletion of insulin-secreting b-cells. The resulting 
insulin deficiency causes chronic hyperglycemia, lead-
ing to typical T1D long-term complications. Prevention 
of these complications is a primary goal in managing 
T1D. In fact, the evolution of the disease can positively 
change if, since its beginning, glycosylated hemoglobin 
is maintained at a level equal or lower than 7.0%1. At the 
diagnosis, most patients may have between 10% and 50% 
of normal pancreatic islet mass. Progressive destruction 
of b-cells accompanies the onset of the typical symp-
toms of T1D in genetically susceptible subjects: poly-
dipsia, polyuria, and weight loss, even with increased 
appetite2. Following the initiation of insulin therapy, T1D 
patients may develop a phase called “honeymoon,” dur-
ing which residual b-cells transiently regain functionality3, 
and patients need lower doses of insulin because of the rela-
tively improved endogenous insulin secretion. Increasing 
insulin requirements are then needed to regulate blood 
glucose. Prevention of further b-cell destruction, through 
the modulation of autoantibody levels, is a pivotal clinical 
target in order to improve metabolic control and to lower 
hypoglycemic episodes and chronic complications4. In 
animal models of nonobese diabetic mice, the immuno-
modulatory therapy was able to slow or prevent the auto-
immune process and the development of T1D5. Favorable 
results have also been shown in immunologic interven-
tions on T1D patients using different immunosuppressive 
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agents6. Physical activity, able to face oxidative stress and 
inflammation, has long been acknowledged as a corner-
stone in the treatment of type 2 diabetes mellitus because 
of its insulin-sensitizer effects. On the other hand, before 
the discovery of insulin, T1D patients were limited in 
their ability to exercise because of the known risks of 
ketosis, dehydration, and management of multiple fac-
tors to maintain normoglycemia. After insulin therapy 
was introduced, a greater awareness was achieved as to 
the potential hypoglycemic events occurring postexercise. 
Recent studies discuss the health benefits of exercise in 
T1D patients7,8. However, improvements in insulin sensi-
tivity can still lead to exercise-induced hypoglycemia. In 
order to reduce this risk, patients may lower their dose of 
short-acting insulin before exercise and eat carbohydrates 
before and during exercise9. Recent observations show 
that physically active T1D subjects, on a balanced caloric 
diet, have a better metabolic control with a residual endo-
crine pancreatic mass10. In a retrospective analysis of a 
T1D population, a subset of patients performing higher 
aerobic activity showed a reduced title of anti-glutamic 
acid decarboxylase (GAD) and anti-islet antigen 2 (IA2) 
compared to sedentary T1D patients7. These findings 
induced us to hypothesize that aerobic physical activity 
may positively regulate autoimmunity in diabetes, pos-
sibly by extending the honeymoon phase, while reducing 
daily insulin requirements and preventing diabetes-
related complications. We tested this hypothesis in non-
obese diabetic mice in a longitudinal study, confirming 
the immunomodulatory potential of aerobic physical 
activity11. This 3-month observational study focuses on 
the effects of different levels of physical activity on meta-
bolic, inflammatory, and autoimmune parameters in T1D 
patients on insulin pump therapy.
MATERIALS AND METHODS
Study Design and Participants
Participants were recruited among T1D patients at the 
endocrinology outpatient clinic of Policlinico San Donato. 
Inclusion criteria were T1D, glycosylated hemoglobin 
<8%, and absence of comorbidities. Recruited subjects 
filled in the Physical Activity Readiness Questionnaire 
(PAR-Q)12 and provided written informed consent prior 
to enrollment into this 3-month observational study. On 
the basis of the Baecke’s exercise activity questionnaire13, 
they were divided into two groups: sedentary (SED) and 
physically active (ACT) subjects, as shown in the flow 
diagram (Fig. 1). Thirteen T1D patients were enrolled 
out of the 20 participants initially screened, 7 sedentary 
(4 males, 3 females; 35.9 ± 8.9 years; BMI: 25.7 ± 3.8) 
and 6 physically active (6 males; 40.5 ± 6.1 years; BMI: 
24.5 ± 2.1). They were all trained on how to use an insu-
lin pump and continuous glucose monitoring (CGM). 
The study was approved by the clinical research ethical 
committee of Policlinico San Donato in accordance with 
the Declaration of Helsinki and Good Clinical Practice 
guidelines.
Physicians were allowed to change antidiabetic medi-
cation regimens during the study, particularly to avoid 
hypoglycemic events. However, major regimen modifi-
cations were not necessary. A glucose level of £70 mg/dl 
was used to define hypoglycemia14.
Analytical Procedures
Blood samples were drawn at baseline and after 
3 months in order to acquire metabolic, autoimmune, 
and inflammatory profiles. Serum aliquots were stored 
at −80°C. All the samples were coded and rapidly trans-
ferred to the central laboratory of Policlinico San Donato, 
where the blood tests were performed.
Metabolic Parameters
The levels of plasma total cholesterol (TC), high- 
density lipoprotein-cholesterol (HDL-C), low-density 
lipoprotein-cholesterol (LDL-C), triglycerides (TG), blood 
glucose, C-peptide, glycosylated hemoglobin (HbA1c), 
and uric acid were determined.
Respiratory Indirect Calorimetry
After an overnight fast, the estimated resting energy 
expenditure (REE) was measured by indirect calorimetry 
(Quark RMR®; COSMED, Rome, Italy). The respiratory 
quotient (RQ) was calculated as the ratio between the vol-
ume of released CO2 (VCO2) and the volume of consumed 
O2 (VO2) derived from the oxidation of the substrates.
Body Composition
Body fat mass and fat-free mass were calculated on 
the basis of data obtained by Dual Energy X-ray Absorp-
tiometry (Lunar DPX-L; Lunar Corp., Madison, WI, 
USA) using bioelectrical impedance analysis (BIA) at 
baseline and at the end of the 3-month study. The Tanita® 
BC-418 (Tanita Corp., Tokyo, Japan) measured body 
composition using a constant current at high frequency 
(50 kHz, 500 µA) supplied from the tips of the toes and 
the fingertips by means of eight electrodes. Voltage was 
measured on the calcaneus and the thenar eminence.
Autoimmunity and Inflammatory Parameters
The levels of the autoantibodies against zinc transporter 
8 (anti-ZnT8), glutamic acid decarboxylase (anti-GAD), 
and tyrosine phosphatase-related islet antigen 2 (anti-IA2) 
were measured using the luminescent immunopreci-
pitation system (LIPS; Promega, Milan, Italy) as previ-
ously described15. Islet cell antibodies (ICA) were detected 
by indirect immunofluorescence in human pancreas. 
Interleukin-6 (IL-6) and tumor necrosis factor-a (TNF-a) 
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were measured by enzyme-linked immunosorbent assay 
(ELISA; Affymetrix eBioscience, San Diego CA, USA).
Monitoring Devices
Participants, trained by a technician on the correct use 
of metabolic control devices, received an insulin pump 
(Animas Vibe®; Movi SpA, Milan, Italy) with infusion sets 
(Inset® II). They were also provided with a CGM device 
(Dexcom G4®; Movi SpA) with its weekly replaceable 
sensors. The insulin pump allows a very accurate admin-
istration of the insulin therapy, with a minimum infusion 
of 0.025 U/h in basal insulin regulation and a minimum 
increase of 0.5 U when infusing a bolus of insulin. The 
CGM consists of three parts: a small sensor placed on the 
Figure 1. Flow diagram for study design and participants. Abbreviations: T1D, type 1 diabetes; HbA1c, glycosylated hemoglobin; PAR-Q, 
Physical Activity Readiness Questionnaire; CGM, continuous glucose monitoring; SED, sedentary group; ACT, physically active group.
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abdomen measures glucose levels up to 288 times/day, 
and a transmitter on top of the sensor wirelessly sends 
data (radiofrequency telemetry) directly to the monitor of 
the insulin pump, which is used as receiver. CGM pro-
vides interstitial fluid glucose levels using glucose oxidase- 
based electrochemical methods. Because of the lag time 
between blood and dermal interstitial glucose concen-
tration, patients were asked to calibrate sensor glucose 
signals against corresponding blood glucose meter levels 
twice a day. Glucose levels measured by CGM were 
extrapolated by averaging readouts from the first and 
the third month of the study. The integrated system is 
equipped with acoustic alarms and a vibration mode; the 
device rings in case of hyperglycemia, hypoglycemia, and 
rapid increase or decrease of glucose levels. Insulin dos-
ages and glucose levels were recorded by the device and 
uploaded by patients through weekly updates within an 
online program to let the physician monitor his patients.
Physical Activity Habits
Participants, either belonging to the SED or ACT group, 
were asked to maintain their physical activity levels—as 
assessed by Baecke’s questionnaire13. However, staff super-
vision in the exercise physiology laboratory at the Univer-
sity of Milan was available to offer recommendations for 
safe and efficient exercise while ensuring stable energy 
intake throughout the entire 3-month study. For monitoring 
dietary intake, all participants filled in a daily diet diary.
Statistical Methods
Shapiro–Wilk statistical test was used to assess the dis-
tribution of variables. For normally distributed quan titative 
variables, Student’s t-test was carried out. Mann–Whitney 
test was used to analyze non-Gaussian quantitative vari-
ables. Categorical variables were evaluated using Fisher’s 
exact test. Data of each parameter, measured at baseline 
and after 3 months, were expressed as mean ± standard 
deviation (SD). Pearson’s correlation test and linear regre-
ssion analysis were also performed. For all tests, differ-
ences were considered statistically significant at p £ 0.05. 
Analyses were carried out with the Statistical Package 
XLSTAT 2014, Excel 2010, and GraphPad Prism 7 (La 
Jolla, CA, USA).
RESULTS
Study Design and Participants
All T1D patients wore an insulin pump and a CGM 
sensor. Table 1 shows the study participants’ character-
istics and blood test changes after the 3-month observa-
tional period.
Metabolic Profiles
Daily glucose level fluctuations, observed in SED 
and ACT T1D patients, are shown in Figure 2A; ACT 
patients maintained a lower median glycemia throughout 
the 3-month period with respect to SED patients. During 
the third month, ACT T1D patients showed a significant 
reduction in the mean glucose levels measured by CGM 
(−9%, p = 0.025) compared to the first month (Fig. 2B). 
Likewise, the frequency of detected glucose levels above 
180 mg/dl significantly decreased in the ACT subjects 
after 3 months (−24.2%, p = 0.032), while the frequency 
of detected glucose levels below 70 mg/dl increased com-
pared to the first month (+34%, p < 0.01). ACT patients 
self-administered a higher number of boli of insulin per 
day compared to SED controls (6.2 ± 2.2 vs. 3.7 ± 0.8 n boli/ 
day, p = 0.056). ACT maintained lower total insulin per 
day compared to SED patients either at baseline or at the 
end of the study (Table 1).
Respiratory Indirect Calorimetry
The indirect calorimetry proved a significant enhance-
ment in the metabolism of SED patients compared to 
their baseline (REE: +7%, p = 0.04).
Body Composition
The analysis of the body composition showed a sig-
nificantly lower fat mass in the upper and lower limbs 
in ACT patients, compared to the SED patients (−50%, 
p = 0.045) at the end of the 3-month time frame (Table 1). 
Glucose levels monitored by CGM and fat mass were 
correlated as outlined in Figure 3.
Physical Activity
After 3 months, the Exercise Activity Questionnaire13 
showed a significantly higher score in the Sport Index 
(+24%, p < 0.01) and in the Physical Activity Index 
(+17.2%, p < 0.01) among the SED patients compared to 
their baseline results.
Autoimmunity and Inflammatory Profiles
After 3 months of study, SED patients showed 
increased levels of IL-6 (+13.0%, p = 0.423) and 
decreased levels of TNF-a (−15.3%, p = 0.625) with 
respect to baseline, although not significantly. Among 
ACT patients, the concentrations of IL-6 and TNF-a 
were found stable throughout the study. The analysis 
of the autoantibodies showed a lower, although not 
significant, level of anti-GAD among ACT patients 
with respect to SED patients, both at baseline (−21.3%, 
p = 0.886) and at the end of the 3-month study (−38.9%, 
p = 0.570). No significant variations were shown, after 
3 months of study, in the analysis of the other investi-
gated autoantibodies (anti-ZnT8 and anti-IA2).
DISCUSSION
This study showed that being physically active is a per 
se factor improving glycemic control in T1D patients. 
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During an observational period of 3 months, ACT sub-
jects’ glycemic values were lower than SED controls as 
indicated by the CGM. In addition, glycosylated hemo-
globin, the main measure of the glycemic control, tended 
to be better in the ACT group, at baseline and after 
3 months, with respect to their SED counterparts. Low 
levels of HbA1c are associated with low requirements of 
exogenous insulin. It is ascertained that exercise increases 
Table 1. Participants’ Profiles and Changes
SED (n = 7) ACT (n = 6)
Baseline 3 Months Baseline 3 Months
Age (Years) 35.9 ± 8.9 40.5 ± 6.1
Men/Women 4/3 6/0
Metabolic profile
Fasting glycemia (mg/dl) 135 ± 45 119 ± 25 115 ± 23 125 ± 81
Glucose CGM (mg/dl) 159 ± 19 163 ± 28 149 ± 23 135 ± 14†
70–180 mg/dl 56.4% ± 18.2% 58.2% ± 14.2% 60.4% ± 8.4% 65.2% ± 6.8%
>180 mg/dl 37.0% ± 21.0% 35.4% ± 19.1% 31.4% ± 11.9% 23.8% ± 6.9%†
<70 mg/dl 6.6% ± 5.7% 6.4% ± 5.5% 8.2% ± 5.7% 11.0% ± 6.0%†
HbA1c (%) 6.8 ± 0.5 6.7 ± 0.4 6.5 ± 0.5 6.2 ± 0.4
(mmol/mol) 50.1 ± 6.1 50.0 ± 4.7 46.8 ± 5.4 44.7 ± 4.8
Insulin boli n/day 4.0 ± 2.6 3.7 ± 0.8 6.0 ± 2.9 6.2 ± 2.2
dose U/day 43.8 ± 24.4 54.4 ± 20.2 35.4 ± 8.8 38.6 ± 2.1
%basal 46% ± 12.3% 50.8% ± 12.8% 42.4% ± 6.1% 46.4% ± 5.1%
%boli 54% ± 12.3% 49.3% ± 12.8% 57.6% ± 6.1% 53.6% ± 5.1%
C-peptide (ng/ml) 0.18 ± 0.26 0.14 ± 0.20 0.05 ± 0.08 0.02 ± 0.01
Total cholesterol (mg/dl) 182 ± 39 201 ± 40 186 ± 36 180 ± 20
HDL-cholesterol (mg/dl) 65 ± 10 66 ± 19 72 ± 28 73 ± 28
LDL-cholesterol (mg/dl) 109 ± 23 111 ± 30 109 ± 43 105 ± 40
Triglycerides (mg/dl) 114 ± 115 189 ± 286 60 ± 34 52 ± 15
Uric acid (mg/dl) 3.9 ± 0.6 3.8 ± 0.9 4.1 ± 0.8 4.1 ± 0.6
Autoimmunity and inflammatory profile
Anti-ZnT8 (A.U.) 14.7 ± 37.6 14.8 ± 37.6 12.1 ± 19.8 16.6 ± 21.3
Anti-GAD (A.U.) 27.0 ± 38.2 35.1 ± 45.2 21.3 ± 39.0 21.4 ± 39.0
Anti-IA2 (A.U.) 7.9 ± 20.2 9.4 ± 24.1 18.7 ± 18.8 20.7 ± 18.4
ICA (negative %) 57% 71% 50% 50%
IL-6 (pg/ml) 2.0 ± 1.5 2.3 ± 1.2 1.8 ± 0.0 1.8 ± 0.0
TNF-a (pg/ml) 5.9 ± 3.9 5.0 ± 0.0 5.0 ± 0.0 5.1 ± 0.2
Body composition (BIA)
Weight (kg) 78.0 ± 16.6 78.2 ± 16.8 79.7 ± 5.1 79.7 ± 5.4
BMI (kg/m2) 25.7 ± 3.8 25.3 ± 3.5 24.5 ± 2.1 24.5 ± 1.9
Total fat mass (%) 24.0% ± 11.7% 23.2% ± 12.7% 13.9% ± 2.7% 13.9 ± 4.1%
Total fat mass (kg) 19.6 ± 11.8 19.0 ± 12.2 11.1 ± 2.4 11.1 ± 3.5
Fat free mass (kg) 58.5 ± 10.6 59.1 ± 12.2 68.4 ± 4.3 68.7 ± 5.0
Fat mass % (trunk) 23.4% ± 11.7% 22.4 ± 13.7% 15.6% ± 3.5% 15.8% ± 5.6%
Fat mass % (limbs) 24.8% ± 12.9% 24.5 ± 12.8% 12.%5 ± 2.6%* 12.2% ± 2.3%‡
Skeletal muscle mass (kg) 15.7 ± 2.9 16.5 ± 4.8 18.3 ± 1.2* 18.4 ± 1.3
Indirect calorimetry
VO2 (L/min) 0.220 ± 0.036 0.238 ± 0.055* 0.241 ± 0.009 0.235 ± 0.038
VCO2 (L/min) 0.188 ± 0.032 0.201 ± 0.040* 0.204 ± 0.009 0.196 ± 0.025
RQ 0.85 ± 0.03 0.85 ± 0.07 0.85 ± 0.06 0.84 ± 0.04
REE (kcal/day) 1550 ± 255 1671 ± 373* 1690 ± 51 1643 ± 256
REE % 92% ± 9% 98% ± 12%* 95% ± 7% 92% ± 11%
Sedentary (SED) and physically active (ACT) T1D patients at baseline and after 3 months of study. Values are expressed as 
mean ± SD. Glucose levels measured by continuous glucose monitoring (CGM) are extrapolated by averaging readouts of 
the first and the third month of the study for “baseline” and “3 months,” respectively. BIA, bioelectrical impedance analysis; 
BMI, body mass index; RQ, respiratory quotient; REE, resting energy expenditure; VCO2, volume of released CO2; VO2, 
volume of consumed O2.
*p £ 0.05 versus SED baseline; †p £ 0.04 versus ACT baseline; ‡p £ 0.05 versus SED 3 months.
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insulin sensitivity and improves b-cell efficiency and 
glucose utilization16,17. These physiological mechanisms 
have also been proven in T1D patients. These effects 
could be favored using an insulin pump17 integrated with 
a CGM system. Introduced in the late 1970s, the insulin 
pump, also known as continuous subcutaneous insulin 
infusion (CSII), is still the gold standard of T1D ther-
apy18, as it is able to simulate the physiologic pancreatic 
secretion of insulin by delivering rapid-acting insulin 
analogs throughout the day. While multiple daily insulin 
injections (MDII) and CSII are both considered effective, 
the latter offers a greater flexibility, allowing a tighter 
and more accurate insulin administration even for small 
quantities19. In fact, management of T1D is essential to 
prevent complications and allow a quality of life similar 
to the nondiabetic population20.
Moreover, in T1D, the insulin-producing b-cells face 
a destruction process in which T cells play a central role. 
Figure 2. (A) Daily glucose fluctuations in sedentary (SED) and physically active (ACT) type 1 diabetes (T1D) patients throughout 
the 3-month study. The middle line indicates the median glucose levels measured by CGM. The dark gray area is bounded by the most 
common glucose measurements (25th to 75th percentile). The lighter gray area is enclosed between the least common values (10th 
to 90th percentile). The dotted line shows the lowest and highest glucose values. (B) Box-and-whisker plot comparing glucose levels 
measured by continuous glucose monitoring (CGM) in SED and in ACT T1D patients during the third month of the study. *ACT 
patients show a significantly lower mean (−9%, p = 0.025) compared to the SED patients. The mean is identified by the “plus” sign. 
The horizontal line within the box indicates the median, the upper and lower limits of the boxes, the interquartile range, and the ends 
of the whiskers 1.5 times the interquartile range.
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In fact, T1D is characterized by an imbalance in the 
Th1/Th2 cytokine ratio. This imbalance may be skewed 
toward an excess of Th1 cytokines, whereas Th2 cyto-
kines are deficient21 (Fig. 4A).
We hereby focused on two particular exercise-modulated 
cytokines: IL-6 and TNF-a. It is now acknowledged that 
IL-6 is released by myocytes after exercise; IL-6 induces 
lipolysis and gene transcription in adipose tissue22. TNF-a, 
a proinflammatory cytokine released by adipocytes, is 
correlated with insulin resistance23. Muscle-derived IL-6, 
by inducing the production of IL-10, indirectly inhibits 
TNF-a7. Fischer observed elevations in IL-6 after intense 
exercise; this effect is considered a positive factor in mod-
ulating the immunological and metabolic responses to 
exercise24. IL-6 is therefore capable to modulate the benefi-
cial exercise effects as it restores the Th1/Th2 equilibrium 
(Fig. 4B). Another study showed that the anti-inflammatory 
effect of exercise, mediated by the upregulation of Th2 
cytokines, may lead to a protective response toward the 
autoimmune process directed to b-cells25.
Among SED patients, a slight increase in IL-6 and a 
small decrease in TNF-a, even if not significant, may show 
a favorable tendency toward an anti-inflammatory pattern 
in our study. Inflammatory and autoimmunity profiles 
resulted beneficially modified in other previous studies6,7, 
probably due to specific exercise intervention setting.
Modification of body composition is typically debated 
in type 2 diabetes as a main feature of several metabolic 
Figure 3. Linear correlation between glucose levels, measured by continuous glucose monitoring, and fat mass percentage in physi-
cally active patients (ACT; black circles) compared to sedentary controls (SED; blank diamonds).
Figure 4. (A) Type 1 diabetes is an immune-mediated process characterized by an imbalance in the Th1/Th2 cytokine ratio. This bal-
ance is skewed toward an excess of Th1 cytokines (IL-2, IFN-g, and TNF-a), whereas Th2 cytokines (IL-4 and IL-10) are deficient. 
(B) Muscle-derived IL-6 induces the production of IL-10, which inhibits TNF-a, a proinflammatory cytokine. IL-6 is therefore capable 
to elicit the beneficial exercise effects as it restores the Th1/Th2 equilibrium.
Delivered by Ingenta to: Universit? degli studi di Milano
IP: 159.149.193.149 On: Tue, 14 Feb 2017 09:24:17
Article(s) and/or figure(s) cannot be used for resale. Please use proper citation format when citing this article including the DOI,
publisher reference, volume number and page location.
30 ADAMO ET AL.
disorders. Yet, T1D subjects often exhibit a mass remod-
eling detrimental to their metabolism26. In our study, a mod-
erately linear correlation between glucose levels and fat 
mass was found in the ACT individuals, confirming the 
enhanced glucose disposal exerted by the augmented 
muscle mass. In the European Prospective Investigation 
into Cancer and Nutrition Study (EPIC)27, the greatest 
reductions in mortality risk were observed between the 
two lowest activity groups. This suggested that efforts 
to encourage even small increases in activity levels of 
sedentary individuals may be beneficial to public health. 
Thus, behavioral strategies favoring an increase in physi-
cal activity, as well as a reduction in sedentary time, may 
be successful also for T1D patients. As expected, ACT 
subjects exhibited better lipid profiles than those in the 
sedentary condition. However, the difference was non-
significant. Lipid metabolism is another key point when 
discussing exercise-related fuel metabolism in T1D indi-
viduals; the relevant literature, in fact, is still contro-
versial28. Supraphysiological insulin levels may impair 
hepatic glucose output and limit the physiological shift 
from glucose to fatty acid oxidation during exercise. 
Even though fatty acid oxidation was not measured in 
this study, lipid metabolism seemed not to be impaired 
in ACT people compared to SED, especially considering 
their TG levels.
The loss of insulin secretion regulation and the conse-
quent need of exogenous insulin predispose to an increased 
risk of exercise-associated glucose fluctuations in indi-
viduals with T1D. This study magnified the risk of hypo-
glycemic events even under the strict control of CSII 
plus CGM. This risk, in fact, cannot be utterly abolished. 
Nonetheless, pump therapy represents one of the most 
cost-effective approaches in different populations with 
T1D29. Hypoglycemia is a relevant barrier for being 
physically active in T1D individuals; exercise profes-
sionals should promote not only greater awareness of 
hypoglycemic/hyperglycemic events during exercise 
but also the potential side effects of suboptimal glucose 
control. Few studies have explored diversified strate-
gies to prevent hypoglycemia in exercising T1D people. 
Some exercise studies on T1D subjects consider carbo-
hydrate supplement30, reduction of preprandial insulin 
doses31, and adjustment of basal insulin infusion in pump 
therapy32. Other studies suggest to perform intermittent, 
very brief (about 10 s) maximal intensity sprints either 
at the beginning33 or at the end34 of a moderate intensity 
exercise session: the hypoglycemia would be attenuated 
by a transient reduction of glucose disposal35. Another 
strategy would consist in performing resistance exer-
cise prior to aerobic physical activity36. On the contrary, 
hyperglycemic episodes may occur following strenuous 
exercise; in this case, a small bolus of a short-acting insu-
lin analog is suggested, or, for insulin pump users, basal 
insulin infusion may be temporarily increased to restore 
euglycemic levels34. At the end of this 3-month observa-
tional period, hyperglycemic events significantly dimin-
ished with respect to baseline in the ACT group, despite 
a putative stress due to exercise; this could be interpreted 
as another cue of a well-controlled monitoring system. 
Besides, ACT patients, compared to SED ones, seemed 
to have a more responsible behavior in the monitoring of 
glucose levels, as witnessed by a favorable ratio between 
boli and doses of infused insulin.
At the hospital outpatient clinic and in the exercise 
physiology laboratory, counseling sessions were success-
fully offered to both groups in the management of the 
disease. Therefore, an educational program addressed to 
T1D patients focused on insulin injection monitoring, diet 
and exercise are strongly recommended. As suggested 
by our indications, especially SED patients may benefit 
from an augmented level of exercise habits by following 
the exercise staff recommendations.
The main limitation of this study is the small sample size. 
An interventional study would have possibly allowed to 
detect significant differences between groups in some fea-
tures (HbA1c, insulin doses, and lipid profiles). However, 
we think that this snapshot is still informative within the 
T1D scenario. Likely, our findings, even if limited, can be 
attributed to the different physical activity levels. Greater 
changes rather than tendencies might be gathered with a 
controlled exercise trial. As such, these observations may 
be meant as primary predictors of the exercise-induced 
metabolic improvements in T1D subjects. Future studies 
should address whether exercise training may impact also 
on autoimmunity beyond inflammatory pattern in individ-
uals affected by T1D or pre-T1D.
CONCLUSIONS
This study highlights that exercise is an independent 
factor for better metabolic profiles in T1D individuals 
on insulin pump therapy. Integrated monitoring systems 
(CSII plus CGM) along with an educational-based app-
roach are efficient in gaining the beneficial effects of 
exercise in the management of T1D. Further interven-
tional studies are advocated for investigating a positive 
exercise-induced immunomodulation.
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